VIP

weak data

Also seen as: Vasoactive Intestinal Peptide

The Dose Guy’s verdict

Aug 29, 2026
3 sources

VIP is two different conversations. One is aviptadil, synthetic VIP tested in real trials for lung disease, where the largest trial failed and smaller ones showed mixed signals. The other is intranasal VIP for chronic inflammatory response syndrome and mold illness, the use case people actually buy it for, which has zero trial data behind it. If you are considering VIP for CIRS, understand that you are running on mechanism logic and community reports, not evidence.

Would I take it?Caution. The CIRS use everyone buys it for has no trial.

What it is

VIP is a 28-amino-acid neuropeptide your body already makes. It works through two receptors, VPAC1 and VPAC2, and the downstream effects are anti-inflammatory: it suppresses TNF-alpha and other inflammatory cytokines, promotes regulatory T cells, and relaxes smooth muscle in the airways and gut. It is a genuine anti-inflammatory signal, not a supplement story.

The clinical version, aviptadil, has been tested intravenously and by inhalation for severe lung disease, mostly in COVID-era respiratory failure. The CIRS community uses it differently: intranasal, at low doses, for months, following a protocol that originated with the Shoemaker framework for mold-related illness. These are functionally different interventions using the same molecule, and the trial data from one does not validate the other. For the standard healing toolkit, BPC-157 and TB-500 cover broader ground. VIP is for a specific inflammatory picture, not general recovery.

What the research shows

The trial program tested VIP for acute lung disease. The CIRS use has no trial:

TESICO, the definitive trial: intravenous aviptadil versus placebo in COVID hypoxemic respiratory failure. No significant improvement on the day-90 clinical outcome, OR 1.11, p=0.54. Day-90 mortality was 38% with aviptadil and 36% with placebo. A clean miss.Lancet Respir Med 2023 · RCT · n=461

A smaller trial of inhaled aviptadil in hospitalized COVID: mean hospital discharge was 7.8 days versus 10 with placebo, p=0.049. The inhaled route showing a signal where IV did not.Multicenter RCT 2025 · n=80

Four weeks of nebulized VIP in active sarcoidosis significantly reduced TNF-alpha production by cells from bronchoalveolar lavage. Open-label, no control, but the anti-inflammatory mechanism showed up where expected.Am J Respir Crit Care Med 2010 · open-label · n=20

No trial has tested intranasal VIP for CIRS, mold illness, or any chronic inflammatory condition. The entire CIRS use case rests on mechanism and community experience.as of Aug 2026

Realistic protocols

The CIRS community runs VIP intranasally, and that is the protocol most readers here care about, even though no trial has tested it. The standard approach is a compounded nasal spray at around 50 mcg per dose, four times daily, for a minimum of 30 days. Some people run longer courses. The logic is that intranasal delivery gets VIP to the upper airways and sinus tissue first, and that the anti-inflammatory effect on the mucosal immune system is what drives the reported symptom relief.

VIP is a large, fragile peptide that clears from blood almost instantly, which is why the intranasal route makes more sense than subcutaneous for this use case: you want local tissue exposure, not systemic levels. Most people source it from compounding pharmacies as a nasal spray rather than reconstituting injectable vials. If you are running it for CIRS, it is typically the last step in a longer protocol that addresses mold exposure, binders, and other interventions first. VIP alone, without addressing the root exposure, is unlikely to do much.

Standard50 mcg 4x/dayIntranasal spray. The community-standard CIRS protocol.

Duration30+ daysMinimum course. Some run longer depending on response.

Timingafter mold protocolVIP is typically the last step, not the first, in CIRS treatment.

Side effects

VIP is an endogenous neuropeptide, and intranasal dosing keeps systemic exposure low, but it is not side-free:

anecdotalNasal congestion and runny nose from the intranasal route, especially early on. Community-reported, no trial has tested this route.

monitorTachycardia and cutaneous flushing occurred during intravenous VIP infusion in a seven-volunteer asthma study. The intranasal CIRS dose is far lower, but flushing, diarrhea and transient blood-pressure drops are widely reported at higher community doses, consistent with VIP’s vasodilatory effects.

monitorIn the TESICO trial, the day-5 composite safety outcome trended higher with aviptadil than placebo. That was IV dosing, not intranasal, but it is a reminder that more VIP is not better.

unknownNo long-term safety data for intranasal VIP in the CIRS population. The trial safety data is all short-term and in acute lung disease, a different context entirely.